Live Breaking News & Updates on Breast Cancer Annual Congress

Stay updated with breaking news from Breast cancer annual congress. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Dr Abdou on Considerations Between AKT vs PI3K Inhibition in HR+/HER2– Breast Cancer

Yara Abdou, MD, discusses the considerations between AKT inhibitors vs PI3K inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.
....

Yara Abdou , School Of Medicine , Division Of Oncology , Lineberger Comprehensive Cancer Center , Department Of Medicine , University Of North Carolina , Breast Cancer Annual Congress , North Carolina , Cancer Annual , Lineberger Comprehensive Cancer Center , Onclive Tv , Breast Cancer ,

Gedatolisib Triplet Shows Early Efficacy in Previously Untreated ER+/HER2– Breast Cancer

The addition of gedatolisib to palbociclib and letrozole produced durable responses with comparable safety to that observed with palbociclib and letrozole alone in treatment-naïve patients with estrogen receptor-positive, HER2-negative advanced breast cancer. ....

San Antonio , United States , San Francisco , Daiichi Sankyo , Gilead Sciences , Helen Diller Family Comprehensive Cancer Center , Boehringer Ingelheim , University Of California , Breast Cancer Annual Congress , Breast Cancer Congress , Esmo Breast Cancer Annual Congress , Antonio Breast Cancer Symposium , Cancer Congress , Odonate Therapeutics , Seattle Genetics , Financial Interests , Cancer Annual Congress , Ucsf Helen Diller Family Comprehensive Cancer Center , Breast Cance ,

Subcutaneous Pertuzumab/Trastuzumab Combo Continues to Prove Safe, Effective in HER2+ Breast Cancer

Subcutaneous delivery of fixed-dose adjuvant pertuzumab plus trastuzumab proved to have favorable tolerability, with a safety profile consistent with that seen with intravenous delivery of the regimen in patients with HER2-positive breast cancer. ....

Baylor University , United States , Daiichi Sankyo , Joyce Oshaughnessy , Pierre Fabre , Baylor University Medical Center , Bristol Myers Squibb , Gilead Sciences , Esmo Breast Cancer Annual Congress , Breast Cancer Annual Congress , Therapy Administration Satisfaction Questionnaire , Cancer Annual Congress , Joyceo Shaughnessy , Texas Oncology , Patient Preference Questionnaire , Healthcare Professional Questionnaire , Alaskan Natives , American Indians , European Journal , Ipsen Biopharmaceuticals , Odonate Therapeutics , Seattle Genetics , Carrick Therapeutics , Breast Cancer , The 2023 Esmo Breast Cancer Annual Congress ,

HER3+ CTC Count May Affect Responses to Patritumab Deruxtecan in Pretreated Advanced Breast Cancer

Higher baseline HER3-positive circulating tumor cell count at baseline and reduction following treatment initiation was associated with a higher likelihood of deriving an early response with patritumab deruxtecan in patients with hormone receptor–positive or HER2-low advanced breast cancer. ....

France General , Gustave Roussy , Barbara Pistilli , Breast Cancer Annual Congress , Cancer Annual , Breast Cancer , The 2023 Esmo Breast Cancer Annual Congress , Phase 2 Icarus Breast01 Trial Nct04965766 , Patritumab Deruxtecan , Her3 Positive Circulating Tumor Cell Count ,

Atezolizumab Plus Trastuzumab/Vinorelbine Elicits Responses in HER2+ Advanced Breast Cancer

Atezolizumab in combination with trastuzumab and vinorelbine generated responses and a tolerable safety profile in patients with HER2-positive, estrogen receptor–negative or ER-positive/PAM50 non-luminal advanced breast cancer, according to data from a prespecified interim analysis of the phase 2 ATREZZO trial. ....

Atezolizumab Tecentriq , Eva Ciruelos Gil , Breast Cancer Annual Congress , Cancer Annual , Breast Cancer , Esmo Breast Cancer Congress , Her2 Positive , Phase 2 Atrezzo Trial , Er Positive Pam50 Non Luminal ,